What To Know About Jefferies’s Downgrade of TCR2 Therapeutics
Jefferies downgraded its rating of TCR2 Therapeutics (NASDAQ:TCRR) to Underperform with a price target of $3.00, changing its…
Jefferies Downgrades TCR2 Therapeutics to Underperform, Lowers Price Target to $3
Jefferies analyst Kelly Shi downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Underperform and lowers the price target from $18 to $3.
Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason
The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…
HC Wainwright & Co. Downgrades TCR2 Therapeutics to Neutral
HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.
Why Is TCR2 Therapeutics Stock Trading Higher Today?
TCR² Therapeutics (NASDAQ: TCRR) shares are trading higher on Monday after the company and Adaptimmune Therapeutics (NASDAQ: ADAP) announced an agreement under which the two companies will combine to create a cell
Where TCR2 Therapeutics Stands With Analysts
TCR2 Therapeutics (NASDAQ:TCRR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Piper Sandler Maintains Overweight on TCR2 Therapeutics, Raises Price Target to $10
Piper Sandler analyst Do Kim maintains TCR2 Therapeutics (NASDAQ:TCRR) with a Overweight and raises the price target from $8 to $10.
EF Hutton Initiates Coverage On TCR2 Therapeutics with Hold Rating, Announces Price Target of $2
EF Hutton analyst Tony Butler initiates coverage on TCR2 Therapeutics (NASDAQ:TCRR) with a Hold rating and announces Price Target of $2.
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 329 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 293 companies set new 52-week lows.